

- (i) at least one marker selected in the group consisting of hsa-miR-34, (in particular hsa-miR-34a and more particularly hsa-miR-34a-5p), hsa-miR-122 (in particular hsa-miR-122-5p) and hsa-miR-192 (in particular hsa-miR-192-5p); and
- (ii) and at least one blood, serum or plasma circulating marker of liver damage.

5

13. The kit according to claim 12, comprising means for determining the level of:


- (i) at least one marker selected in the group consisting of hsa-miR-34, (in particular hsa-miR-34a and more particularly hsa-miR-34a-5p), hsa-miR-122 (in particular hsa-miR-122-5p) and hsa-miR-192 (in particular hsa-miR-192-5p); and

- 10 (ii) and at least one blood, serum or plasma circulating marker of liver damage corresponding used in the method according to any one of claims 1 to 11.

14. Use of an anti-NASH molecule in the manufacture of a medicament for the treatment of NASH, wherein said anti-NASH molecule is to be administered to a patient in need thereof

15 diagnosed with NASH or classified according to the method of any one of claims 1 to 11, in particular classified as receiver of a treatment for NASH.

15. The use according to claim 14, wherein said molecule is of formula (I):



20 wherein:

X₁ represents a halogen, a R₁, or G₁-R₁ group;

A represents a CH=CH or a CH₂-CH₂ group;

X₂ represents a G₂-R₂ group;

G₁ and G₂, identical or different, represent an atom of oxygen or sulfur;

25 R₁ represents a hydrogen atom, an unsubstituted alkyl group, an aryl group or an alkyl group that is substituted by one or more halogen atoms, an alkoxy or an alkylthio group, cycloalkyl groups, cycloalkylthio groups or heterocyclic groups;

R₂ represents an alkyl group substituted by at least a -COOR₃ group, wherein R₃ represents a hydrogen atom, or an alkyl group that is substituted or not by one or more

30 halogen atoms, cycloalkyl groups, or heterocyclic groups.

R₄ and R₅, identical or different, representing an alkyl group that is substituted or not by one or more halogen atoms, cycloalkyl groups, heterocyclic groups; or a pharmaceutically acceptable salt thereof.

16. The use according to claim 14 or 15, wherein the compound is selected in the group consisting of 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-1-one, 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-isopropoxy carbonyldimethylmethoxyphenyl]prop-2-en-1-one, 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyldimethylmethoxyphenyl] prop-2-en-1-one, 1-[4-trifluoromethylphenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyl dimethylmethoxyphenyl]prop-2-en-1-one, 1-[4-trifluoromethylphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-1-one, 1-[4-trifluoromethyl oxyphenyl]-3-[3,5-dimethyl-4-tertbutyloxycarbonyldimethylmethoxy phenyl] prop-2-en-1-one, 1-[4-trifluoromethoxyphenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxyphenyl]prop-2-en-1-one, 2-[2,6-dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic acid, and 2-[2,6-dimethyl-4-[3-[4-(methylthio) phenyl]-3-oxo-propyl]phenoxy]-2-methyl-propanoic acid isopropyl ester; or a pharmaceutically acceptable salt thereof, in particular 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethoxy phenyl]prop-2-en-1-one or a pharmaceutically acceptable salt thereof.